BridgeBio Oncology Therapeutics Inc. Common Stock (BBOT)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business. BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company with no product revenue; it is developing BBO-8520, which is in Phase I for KRASG12C mutant non-small cell lung cancer, and BBO-11818. That means no customer relationships, no pricing power, and no measurable moat—only the possibility of scientific success. The filed numbers are sobering. In fiscal Q2 2026, ended 2026-06-30, the company reported a net loss of $56.5 million, compared with a $28.4 million loss in fiscal Q2 2025. For FY2025, the net loss was $134.0 million, worse than FY2024's $74.3 million loss. Trailing free cash flow was negative $151.6 million, a negative 64.1% yield against a $236.5 million market cap. FairStock's Piotroski score is 0/9 and its Altman Z-score is 1.56, both suggesting financial stress. The one balance-sheet comfort is low leverage, with D/E of 0.01. At the 2026-10-13 close of $2.95, FairStock calculates P/B at 0.73, so shares trade below stated book value. A Graham-style investor might notice that, but in a loss-making biotech, book value can be consumed by research spending. The stock is near its 52-week low of $2.93 and far below its $14.87 high. With a FairStock Score of 32/100 and a Lynch category of none—because of losses in each of the last three years—this is a speculative bet on drug trials, not a proven business with a margin of safety.

In plain English: BridgeBio Oncology Therapeutics is a small drug company with 88 employees. It has no product sales yet and is spending money on early human tests, so it loses millions of dollars. At $2.95 a share, the price looks less expensive than the company's reported accounting value, but the business itself looks weak because it has no revenue and is burning cash.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer